Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor-Reference-Cited by-同舟云学术

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor

Published:2021-04 Issue:4 Volume:128 Page:624-626
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Magone M. Teresa^ORCID,Hartley Iris R.,Fitzgibbon Edmond,Bishop Rachel,Arango Mike,Moran Susan^ORCID,Vold Roo,Rivero Jaydira del^ORCID,Pozo Karen,Streit Jamie^ORCID,Roszko Kelly L.,Collins Michael T.,Gafni Rachel I.

Publisher

Elsevier BV

Subject

Ophthalmology

Reference7 articles.

1. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application;Chae;Oncotarget,2017

2. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma;Javle;J Clin Oncol,2018

3. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology;Klenkler;Exp Eye Res,2004

4. The corneal basement membranes and stromal fibrosis;Medeiros;Investig Ophthalmol Vis Sci,2018

5. Fibroblast growth factor 2 as an antifibrotic: antagonism of myofibroblast differentiation and suppression of pro-fibrotic gene expression;Dolivo;Cytokine Growth Factor Rev,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia;Journal of Medicinal Chemistry;2024-09-11

2. Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report;Translational Cancer Research;2024-05

3. Ocular toxicities of fibroblast growth factor receptor inhibitors: A review;Survey of Ophthalmology;2024-01

4. Eyes on the Lid: The Impact of Fibroblast Growth Factor Receptor Targeting Drug on Human Meibomian Gland;Eye & Contact Lens: Science & Clinical Practice;2023-11-21

5. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements;Cureus;2023-10-10